Αρχική World News Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with... World News Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL Από Ogkologos - 25 Φεβρουαρίου, 2025 1056 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR TRACERx EVO, a new programme to transform lung cancer research 9 Νοεμβρίου, 2022 UK Clinical Trial Compares E-cigarettes, Nicotine-Replacement Products for Smoking Cessation 8 Μαρτίου, 2019 Developing Biomarkers for Immunotherapy: A Conversation with Drs. Magdalena Thurin and... 27 Ιουλίου, 2018 Dexrazoxane Protects the Heart Long Term for Kids Being Treated for... 16 Μαρτίου, 2023 Φόρτωση περισσοτέρων HOT NEWS Helping Cancer Survivors Cope with Cancer-Related Anxiety and Distress Can cancer cells communicate? Pralsetinib: Measures to Minimise Increased Risk for Tuberculosis Benefit Assessment of Adding Irinotecan to Capecitabine-Based Neoadjuvant Chemoradiation for Locally...